Viking Therapeutics Faces Setback Amid Obesity Drug Competition
Viking Therapeutics' stock fell by about 11% after announcing trial results for its weight-loss drugs, despite showing a placebo-adjusted average weight loss of up to 6.8% in the oral version. Analysts expressed concerns over the high costs and challenges of scaling production for both oral and injectable forms, suggesting that established companies like Eli Lilly and Novo Nordisk have significant competitive advantages. Viking's shares have seen substantial gains this year, but the path to market remains long and costly.
